Designation of Susoctocog Alfa as an Orphan drug - Baxter Healthcare Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework governing the manufacture, importation, supply, and advertising of therapeutic goods. The Act is administered by the Therapeutic Goods Administration (TGA), a department within the Australian Government's Department of Health. The policy objective of the Therapeutic Goods Act 1989 is to protect public health by regulating therapeutic goods, ensuring that only products meeting safety, quality, and efficacy standards are available to consumers. In line with this objective, the Act includes provisions for the designation of orphan drugs, which are medications developed for the treatment of rare diseases. The designation aims to encourage the development of treatments for conditions that might otherwise be neglected due to their low prevalence.

Scope and Application

The Therapeutic Goods Act 1989, as amended and applied through the Therapeutic Goods Regulations 1990, governs the regulation of therapeutic goods in Australia. Specifically, the gazetted designation of susoctocog alfa as an orphan drug under this Act pertains to its use in the treatment and prevention of serious bleeding episodes in patients diagnosed with acquired haemophilia A. This designation is effective from 3 July 2014, and the relevant dose form, powder for injection, is specified for this therapeutic use. The sponsor responsible for susoctocog alfa is Baxter Healthcare Pty Ltd. The Act applies to entities involved in the supply, importation, or research of therapeutic goods within Australia, encompassing both individuals and corporate bodies. The scope of this designation extends across the Commonwealth, impacting all states and territories uniformly. Exclusions and exemptions under this specific designation are not explicitly detailed in the gazette but would typically align with the general provisions of the Therapeutic Goods Act and associated regulations, which may include exclusions for certain research activities under specific conditions or exemptions for small quantities used in clinical trials. The application and enforcement of these provisions may be further defined or refined through subordinate instruments, ensuring that the therapeutic landscape in Australia is both regulated and adaptive to advancements in medical science.

Key Provisions

The Therapeutic Goods Act 1989, through its regulations, allows for the designation of certain drugs as orphan drugs under specific circumstances. In this instance, the Delegate of the Secretary, Dr. Anthony Gill, has designated susoctocog alfa as an orphan drug under section 16J of the Therapeutic Goods Regulations 1990. This designation (sections 16J(1) and 16J(2)) is specifically for the treatment and prevention of serious bleeding episodes in patients with acquired haemophilia A, and it is applicable to the powder for injection form of the drug. The sponsor of susoctocog alfa is identified as Baxter Healthcare Pty Ltd. This designation is crucial as it provides certain incentives and regulatory advantages for drugs that treat rare conditions, potentially facilitating their development and availability. The obligations imposed on the parties involved by this designation include those of the sponsor, Baxter Healthcare Pty Ltd, and potentially other entities involved in the manufacture, supply, or importation of susoctocog alfa. The sponsor is responsible for ensuring that the drug meets the necessary quality, safety, and efficacy standards as outlined in the Therapeutic Goods Act and its regulations. Additionally, the sponsor must comply with any specific requirements or conditions associated with the orphan drug designation, such as providing data on the drug’s effectiveness and safety, and ensuring that the drug is manufactured according to Good Manufacturing Practice (GMP) standards. Failure to comply with the provisions of the Therapeutic Goods Act or the Therapeutic Goods Regulations can result in various consequences. For instance, breaches of the Act or Regulations can lead to civil or criminal penalties. Civil penalties can include fines, and in severe cases, criminal penalties such as imprisonment may apply. The maximum penalties can vary depending on the specific breach and the circumstances surrounding it, but they are designed to enforce compliance and protect public health. Additionally, the Therapeutic Goods Administration (TGA) has the authority to take action against non-compliant products, such as recalling them from the market or prohibiting their importation or supply. These measures are crucial in maintaining the integrity of the therapeutic goods regulatory framework in Australia.